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Abstract
Background: Cytomegalovirus (CMV), Epstein Barr virus (EBV) and varicella-zoster virus (VZV) are common
herpesviruses frequently acquired in childhood, which establish persistent, latent infection and are likely to
impact the developing immune system. Little is known about the epidemiology of CMV and EBV infections
in contemporary UK paediatric populations, particularly whether age at infection differs by ethnic group.
Methods: Children enrolled in the Born in Bradford Allergy and Infection Study had a blood sample taken and a
questionnaire completed at 12 and 24 months of age. Ordered logistic regression quantified associations between
ethnicity and other risk factors and age at CMV/EBV/VZV infection (<12 months, 12–24 months, uninfected at 24 months).
Results: Pakistani children (n = 472) were more likely to be infected with CMV and EBV at a younger age than White
British children (n = 391) (CMV: adjusted odds ratio (OR) 2.53, 95% confidence interval (CI) 1.47–4.33; EBV: adjusted OR
2.16, 95% CI 1.43–3.26). Conversely, Pakistani children had lower odds of being VZV infected in the second year than
White British children (adjusted OR 0.57, 95% CI 0.33–0.97). There was a strong association between increasing birth
order and later CMV infection in Pakistani children.
Conclusions: We report large differences in CMV and EBV incidence in the first 2 years between Pakistani and White
British children born in Bradford, which cannot be explained by differences in risk factors for infection. Our data will
inform the optimum schedule for future CMV and EBV vaccination programmes.
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Background
Cytomegalovirus (CMV), Epstein Barr virus (EBV) and
varicella-zoster virus (VZV) are common herpesviruses
frequently acquired in childhood. They establish persist-
ent, latent infection and are likely to impact the develop-
ing immune system [1, 2]. In childhood, VZV causes
chickenpox but CMV and EBV infections are usually
asymptomatic. If acquired in adolescence, EBV can cause
glandular fever. EBV has been associated with immune
disorders such as multiple sclerosis and lymphoma [3, 4]
and CMV seropositivity is associated with inflammation,
atherosclerosis and immunosenescence [5, 6].
Chickenpox vaccination is not part of the UK routine
childhood vaccination programme but zoster vaccine
has been introduced for adults in their 70s to prevent
shingles [7], while CMV and EBV vaccines are under
development [8–10]. Population-based data on the age-
specific prevalence and incidence of these viruses is
needed to inform the timing and target groups of poten-
tial vaccination programmes. Little is known about the
epidemiology of CMV and EBV in contemporary paedi-
atric UK populations, particularly in different ethnic
groups. A recent US study identified differences in CMV
seroprevalence by ethnic group among children but had
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limited data on other relevant variables such as childcare
and breastfeeding [11].
The Allergy and Infection Study is a sub-study of the
Born in Bradford birth cohort and aims to describe the
maternal and paediatric epidemiology of CMV, EBV and
VZV infection and to investigate the effect of age at in-
fection on immune function and atopic allergy. The
specific objectives of this paper are to estimate the inci-
dence of CMV, EBV and VZV infection at age 1 and
2 years and to identify factors associated with infection,
in particular to quantify any differences in age at infec-
tion by ethnic group.
Methods
Children enrolled in the Born in Bradford cohort who
were born on or after 1 March 2008 with a maternal
baseline questionnaire available were eligible for the Al-
lergy and Infection Study (ALL IN). Details of the Born
in Bradford (BiB) cohort are described elsewhere [12].
Briefly, BiB is a multi-ethnic birth cohort study aiming
to examine the impact of environmental, psychological
and genetic factors on maternal and child health. Bradford
is a city in the North of England with high levels of socio-
economic deprivation and ethnic diversity.
Mothers were invited to participate in ALL IN 1 month
before their child’s first birthday. A questionnaire was
completed by those who consented and a 5 ml venous
blood sample was taken from the child, centrifuged and
stored at -80 °C. This was repeated 1 year later to pro-
vide exposure data and serum at 12 and 24 months. See
Additional file 1 for further details.
A sample of 1000 children was selected for serological
testing (see Additional file 1 for sample size calcula-
tions); 700 based on having 4 or 5 aliquots of the 24-
month sample and having received the relevant immuni-
sations (for a separate analysis of response to routine
vaccination) and 300 randomly selected from those with
fewer than 4 aliquots.
At the Royal Free Virology laboratory, the 24-month
samples were tested first for CMV-immunoglobulin G
(IgG), EBV-IgG and VZV-IgG. If positive, the 12-month
sample was tested in the same way. CMV-IgG was tested
using the Abbott Architect assay (kit product no. 6c15-25)
and EBV-IgG and VZV-IgG using the Diasorin Liaison
assays (kit product numbers 310510 and 310850, respect-
ively) [13]. For children who were CMV-IgG positive at
12 months, the cord blood sample was tested for CMV-
deoxyribonucleic acid (DNA) using a quantitative real-
time polymerase chain reaction method described in detail
elsewhere [14]. To verify the expected loss of maternal
antibody by 12 months so that IgG testing at this age can
represent paediatric infection, a random sample of 100
children who were IgG negative at 24 months for each in-
fection were tested for IgG at 12 months.
Data management and key variables
Data from several sources were combined: the maternal
baseline questionnaire for the main BiB study, the ma-
ternity database (eClipse), the ALL IN questionnaire
datasets (12- and 24-month) and the serology results.
Outcome variable: For each of the three infections,
IgG results at 12 and 24 months were combined to create
an age at infection variable for each child with three
categories: infected by 12 months, infected between 12
and 24 months and uninfected at 24 months.
Explanatory variables: The main exposure of interest is
ethnicity, defined as mother’s ethnic group and cultural
background self-reported at the baseline interview dur-
ing pregnancy, in three categories: White British, Paki-
stani and Other. Potential confounders are factors which
influence exposure to infection via contact with the
mother, siblings and others, especially children: birth
order [15], breastfeeding [16, 17], household size/compos-
ition [15], childcare [18, 19], bedroom sharing [20, 21] and
attendance at mother/baby activities [20]. We also con-
sidered socio-economic indicators (maternal education,
home ownership) which may act as proxies for exposure
to infection [11, 22].
Parents were asked for details of all regular childcare
arrangements, defined as at least 5 h per week for a dur-
ation of at least 1 month. The hours at each childcare
arrangement were calculated by: number of months at-
tending the childcare arrangement (age 12 m question-
naire completed minus age started arrangement) x hours
per week x 4.35 x weight for number of other children.
The child-hours at each arrangement were added to ob-
tain the total child care hours for each child. This was
adapted from the method first used by Ma et al. [19].
Total child care hours were calculated separately for in-
formal (looked after by family members/friends) and for-
mal (childminder/nursery) arrangements. Data collected
on breastfeeding at the 12- and 24-month visits were
combined to create an ever/never breastfed variable and
a breastfeeding duration variable.
Data on several variables were collected at more than
one time point. Decisions were made a priori about
which to include as follows: CMV—as most infections
were acquired in the first year and the greatest difference
between ethnic groups is in the first 12 months, child-
care up to the 12-month visit was used, total number of
members of household at baseline questionnaire was
used rather than at 12-month visit, and the summary
bedroom sharing variable used referred to the first
12 months. EBV—although there were differences by
ethnic group in the first 12 months and from 12 to
24 months, most infections were acquired between 12
and 24 months. Household size and number of children
in the household collected at the 12-month visit were
used rather than the baseline questionnaire data, and
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bedroom sharing from 12 months collected at the 24-
month visit was included. VZV—the difference between
ethnic groups is at 12–24 months so the same variables
were used as for the EBV analysis.
Statistical methods
All data analysis was conducted using Stata version 13 [23].
To quantify the associations between age at CMV/
EBV/VZV infection and risk factors for infection, or-
dered logistic regression was used, excluding 137 chil-
dren who were not White British or Pakistani to focus
the comparison between the two main groups. The
resulting odds ratios are for infection by 12 months
compared to infection between 12 and 24 months and
infection between 12 and 24 months compared to unin-
fected at 24 months, i.e. the odds ratio compares each
category with the next and the steps between categories
are assumed to be equal. This proportional odds assump-
tion was checked for each of the variables included. For
the unstratified multivariable model of age at VZV infec-
tion, multinomial logistic regression was used as the pro-
portional odds assumption was not satisfied.
First, multivariable models quantified the difference in
age at infection between White British and Pakistani
children, adjusting for other risk factors for infection.
Due to differences in the prevalence of potential risk fac-
tors for infection between the White British and Pakistani
children, analyses were then stratified by ethnic group to
identify the most important risk factors in each group.
Most variables were included a priori as factors which
influence exposure to infection. As some variables were
likely to be highly correlated (e.g. birth order and number
of children in household), likelihood ratio tests deter-
mined which of each pair should be retained in the model.
Socio-economic factors were then added to the model and
retained if the univariable p value was <0.05 or the likeli-
hood ratio test p value for inclusion in the multivariable
model was <0.05. Maternal age was included a priori in
the CMV models as a proxy for maternal serostatus
(CMV seropositivity increases with age). The timing of
blood collection visits varied around 12 and 24 months of
age; as the chance of a seropositive result would increase
with age, the actual age at the planned 24-month blood
sample variable was included in multivariable models.
Results
Of 7423 eligible children, the parents of 5891 were con-
tacted and invited to take part in ALL IN and 3196 (54%)
agreed. Of the 2695 parents who declined, 2013 gave a
reason: 1075 (53%) not happy about having blood samples
taken, 510 (25%) too busy and 428 (21%) gave other rea-
sons. Figure 1 shows the number of children completing a
12- and 24-month visit. The children recruited were born
between March 2008 and June 2011.
Of the 24-month samples, there were 5 equivocal results
for VZV which were considered negative. One-third of
children (323) were seronegative for all three infections
and 677 seropositive for at least one. A 12-month sample
was not available for 58 of 677 children so 12-month sam-
ples for 619 children were tested. 231 children were
CMV-IgG positive at 12 months. Cord blood was available
for 154 of these; one child had detectable CMV-DNA
(52,268 CMV VL genomes/ml) while 153 were undetect-
able (<200 copies/ml). Testing to verify loss of maternal
antibody gave the following results: For EBV none of the
101 children who were IgG negative at 24 months were
IgG positive at 12 months. For CMV two of 103 children,
and for VZV two of 101 children, who were IgG negative
at 24 months were IgG positive at 12 months (with the
same results on re-testing).
This analysis includes 1000 children with CMV, EBV
and VZV infection status at 12 and 24 months. 391
(39%) children were born to White British women, 472
(47%) to Pakistani women and 137 (14%) to women of
other ethnic groups (Table 1). Table 1 shows the charac-
teristics of the children and their mothers by ethnic
group (also see Additional file 2).
The 1000 children selected for this analysis were simi-
lar to the ALL IN children who were not included with
respect to ethnic group, mother’s country of birth, sex,
childcare, household size and number of children in the
household but were more likely to have been breastfed
(81% vs. 74%). Compared to the rest of the BiB cohort
(12,538 children), the 1000 ALL IN children were similar
in terms of most characteristics but their mothers were
slightly more likely to be married and living with partner
(72% vs. 65%) and to be in the least deprived quintiles of
the Index of Multiple Deprivation.
There were marked differences in the incidence of CMV
and EBV infection at 12 and 24 months between the
White British and Pakistani children with the Pakistani
children infected earlier (Fig. 2 and Additional file 3).
CMV
One-third of Pakistani children (162, 34%) were infected
by 12 months compared to 9% (36) of White British
children, with a further 10% (47) and 6% (25) respect-
ively infected between 12 and 24 months. In un-
adjusted analysis there was a 4-fold increase in odds of
being infected by 12 months than between 12 and
24 months or infected between 12 and 24 months than
uninfected at 24 months in Pakistani children com-
pared to White British children (odds ratio (OR) 4.44,
95% confidence interval (CI) 3.20–6.14, <0.001). This
association attenuated with adjustment for covariates
(birth order, household size, breastfeeding duration,
bedroom sharing, childcare, mother/baby activities,
travel outside Europe, maternal age, mother’s country
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Fig. 1 Children included in the Born in Bradford Allergy and Infection Study
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Table 1 Characteristics of the children and their mothers
All (n = 1000) White British (n = 391) Pakistani (n = 472)
Mother’s baseline questionnaire
Mother’s ethnic group
White British 391 (39%)
White Other 26 (3%)
Mixed-White and Black 8 (1%)
Mixed-White and South Asian 5 (1%)
Black 17 (2%)
Indian 42 (4%)
Pakistani 472 (47%)
Bangladeshi 15 (1%)
Other 24 (2%)
Mother’s country of birth
UK & Ireland 612 (61%) 386 (99%) 177 (38%)
Elsewhere 388 (39%) 5 (1%) 295 (62%)
Mother’s age at recruitment (yrs)
mean, SD, range
28.9, 5.57, 15–44 28.9, 5.96, 15–43 28.8, 5.28, 17–44
Marital & cohabitation status combined
Married and living with partner 716 (72%) 167 (43%) 445 (94%)
Not married and living with partner 170 (17%) 146 (37%) 1
Not living with partner 113 (11%) 77 (20%) 26 (6%)
missing (married, cohab status missing) 1 1 0
Birth order
1 367 (37%) 184 (47%) 126 (27%)
2 289 (29%) 128 (33%) 107 (23%)
3–4 290 (29%) 72 (18%) 194 (41%)
5+ 54 (5%) 7 (2%) 45 (9%)
Total no. of household members
median, IQR, range 4, 3–5, 1–16 3, 2–3, 1–8 5, 4–7, 2–16
missing 1 1 0
No. of household members under 16 years
median, IQR, range 1, 0–2, 0–7 1, 0–1, 0–6 2, 1–3, 0–7
missing 1 1 0
Mother’s highest educational qualification (equivalised)
< 5 GCSE equivalent 200 (20%) 59 (15%) 130 (28%)
5 GCSE equivalent 253 (25%) 98 (25%) 135 (29%)
A level equivalent 147 (15%) 72 (18%) 55 (12%)
higher than A level 313 (31%) 118 (30%) 134 (28%)
Other/don’t know/foreign unknown 86 (9%) 44 (11%) 17 (3%)
missing 1 0 1
Mother’s employment status
Currently employed 461 (46%) 279 (71%) 94 (20%)
Previously employed 238 (24%) 91 (23%) 117 (25%)
Never employed 300 (30%) 21 (5%) 261 (55%)
missing 1
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Table 1 Characteristics of the children and their mothers (Continued)
Father’s employment status
Employed non-manual 414 (44%) 215 (59%) 135 (30%)
Employed manual 298 (31%) 85 (23%) 172 (38%)
Self-employed 166 (17%) 38 (10%) 111 (25%)
Student 9 (1%) 4 (1%) 2
Unemployed 54 (6%) 21 (6%) 28 (6%)
Don’t know 5 (1%) 4 (1%) 1
missing 54 24 23
Mother smoked during pregnancy
Yes 135 (14%) 110 (28%) 15 (3%)
No 863 (86%) 281 (72%) 456 (97%)
missing 2 1
Index of Multiple Deprivation (IMD) 2010 quintile (national)
1 (most deprived) 640 (64%) 162 (41%) 387 (82%)
2 164 (16%) 87 (22%) 49 (10%)
3 141 (14%) 94 (24%) 30 (6%)
4 35 (4%) 31 (8%) 4 (1%)
5 (least deprived) 20 (2%) 17 (4%) 2
Maternity records
Parity (registerable)
median, IQR, range
1, 0–2, 0–7 1, 0–1, 0–6 2, 0–3, 0–7
missing 26 10 14
Gestational age (to last completed week)
median, IQR, range
39, 38–40, 29–44 40, 38–40, 29–44 39, 38–40, 20–42
missing 6 2 3
Birth weight (g)
median, IQR, range
3280, 2920–3610,
890–4904
3400, 3050–3710,
890–4820
3180, 2880–3490,
1275–4520
missing 6 2 3
Route of birth
vaginal 783 (79%) 296 (76%) 387 (83%)
caesarean 211 (21%) 93 (24%) 82 (17%)
missing 6 2 3
Sex of baby
Male 531 (53%) 190 (49%) 262 (55%)
Female 469 (47%) 201 (51%) 210 (44%)
ALL IN questionnaires
Ever breastfed 806 (81%) 289 (74%) 386 (82%)
Never breastfed 192 (19%) 102 (26%) 84 (18%)
missing 2 0 2
Duration of breastfeeding
never 192 (19%) 102 (26%) 84 (18%)
< =4 weeks 210 (21%) 99 (25%) 91 (19%)
1–6 months 243 (24%) 95 (24%) 121 (26%)
6–12 months 219 (22%) 65 (17%) 102 (22%)
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Table 1 Characteristics of the children and their mothers (Continued)
> 12 months 131 (13%) 29 (7%) 70 (15%)
missing 5 1 4
Bedroom/bed sharing
Shared bedroom up to 6 mths: Yes 912 (92%) 323 (83%) 463 (99%)
No 82 66 5
missing 6 2 4
Shared bedroom from 6 mths to 12mth visit: Yes 716 (72%) 170 (44%) 439 (94%)
No 278 219 29
missing 6 2 4
Shared bedroom from 12 mths: Yes 688 (69%) 143 (37%) 448 (95%)
No 312 248 24
Shared bed from 12 mths: Yes 273 (27%) 27 (7%) 204 (43%)
No 726 364 267
missing 1 1
Childcare
Ever regular childcare by 12 m visit 348 (35%) 228 (58%) 63 (13%)
Never regular childcare by 12 m 646 161 405
missing 6 2 4
Ever regular childcare by 24 m visit 426 (43%) 266 (68%) 92 (19%)
Never regular childcare by 24 m 574 (57%) 125 (32%) 380 (81%)
Mother & baby activities up to 6 m
Rarely 634 (64%) 169 (44%) 383 (82%)
At least once a month 41 (4%) 24 (6%) 11 (2%)
Usually once a week 191 (19%) 104 (27%) 55 (12%)
More than once a week 126 (13%) 91 (23%) 18 (4%)
missing 8 3 5
Mother & baby activities 6 m to 12 m visit
Rarely 593 (60%) 175 (45%) 337 (72%)
At least once a month 66 (7%) 32 (8%) 26 (6%)
Usually once a week 203 (20%) 92 (24%) 79 (17%)
More than once a week 132 (13%) 90 (23%) 26 (5%)
missing 6 2 4
Ever travelled outside UK up to 12 m visit
No 773 (78%) 320 (82%) 373 (79%)
Within Europe 93 (9%) 61 (16%) 4 (1%)
Outside Europe 128 (13%) 7 (2%) 92 (20%)
missing 6 3 3
Travelled outside UK since 1st birthday (up to 24 m visit)
No 686 (69%) 271 (69%) 343 (73%)
Within Europe 155 (15%) 110 (28%) 12 (2%)
Outside Europe 159 (16%) 10 (3%) 117 (25%)
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of birth, home ownership and age blood sample taken)
but there remained strong evidence of a 2.5-fold increase
in odds of earlier infection among Pakistani children
compared to White British children (adjusted OR = 2.53,
95% CI 1.47–4.33, p = 0.001).
Maternal infection status was only available for 90
children; 71/90 (79%) mothers were CMV seropositive
(52% (17/33) of White British and 94% (48/51) of Pakistani
women). Among the children of seropositive mothers, 3/
17 (18%)White British children were infected by 12 months
compared to 14/48 (29%) Pakistani children. An adjusted
sub-group analysis was not possible due to small numbers
in some groups but the pattern of earlier infection among
Pakistani children remains.
To identify the most important risk factors in each
group, the adjusted analysis was run separately for
White British and Pakistani children (Table 2). The key
associations are summarised in Table 5. Of particular
note, among the Pakistani children increasing duration
of breastfeeding was strongly associated with earlier in-
fection whereas among White British children earlier in-
fection was only evident for those breastfed for
6 months or more. There was a strong association be-
tween increasing birth order and later age at infection in
the Pakistani children such that children with one or
more older siblings had 60% lower odds of being in-
fected by 12 months or between 12 and 24 months than
first-born children. The birth order estimates for White
British children were in the same direction but no statis-
tically significant association was observed.
EBV
7% (28) of White British children were infected by
12 months compared to 21% (101) of Pakistani children
and a further 18% (71) and 30% (140) respectively were
infected between 12 and 24 months. In unadjusted or-
dered logistic regression analysis, Pakistani children had
three times the odds of being EBV infected by 12 months
than between 12 and 24 months or between 12 and
24 months than to remain uninfected at 24 months than
the White British children (OR 3.14, 95% CI 2.36–4.18,
p <0.001). When adjusting for birth order, household
size at 12 months, bedroom sharing in the first year,
breastfeeding duration, formal childcare hours in the
first and second years, mother/baby activities in the first
year, travel outside Europe since first birthday, maternal
age, maternal education and age blood sample taken,
Pakistani children had twice the odds of being infected
earlier than White British children (adjusted OR 2.16,
95% CI 1.43–3.26, p < 0.001).
The analysis was stratified by ethnic group (Table 3),
with key associations summarised in Table 5. The unex-
pected strong association between later infection and
mother/baby activities is limited to White British children
who had ever attended childcare and relates to attendance
between 6 and 12 months (rather than <6 months) but
there was no clear dose-response relationship with the
original 4-category variable. In multivariable analysis
among White British children, the odds ratios for the
original variable for mother/baby activities between 6
and 12 months were around 0.5 but only one was of
(borderline) statistical significance (p = 0.05).
VZV
The incidence of VZV infection at 12 months was simi-
lar for Pakistani and White British children (10% and 9%
respectively) but between 12 and 24 months incidence
was higher in the White British children (23% vs. 14% in
the Pakistani children). In unadjusted multinomial logis-
tic regression analysis, there was no difference in the
proportion of children infected by 12 months by ethnic
group (OR 1.00, 95% CI 0.62–1.60) but Pakistani chil-
dren had nearly 50% lower odds of being infected be-
tween 12 and 24 months than White British children
(OR 0.53, 95% CI 0.37–0.76, p = 0.001). This association
remained, although with wider confidence intervals, after
adjusting for birth order, household size at 12 months,
breastfeeding duration, formal childcare hours in first
and second years, bedroom sharing in the second year,
mother/baby activities in the second year, maternal age
and age blood sample taken: by 12 m adjusted OR 0.83,
95% CI 0.41–1.68, p = 0.60; 12–24 m adjusted OR 0.57,
95% CI 0.33–0.97, p = 0.04.
Results of the multivariable ordered logistic regression
analysis, stratified by ethnic group, are shown in Table 4.
Higher birth order was associated with earlier VZV infec-
tion in White British and Pakistani children, with second-
born children having the highest odds of earlier infection.
Among the Pakistani children, for every year increase in
maternal age there was a 5% decrease in odds of early
VZV infection (Table 4).
Fig. 2 Incidence of CMV, EBV and VZV infection at 12 and 24 months
by ethnic group
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Discussion
One-third of Pakistani children were CMV infected in the
first year compared to 9% of White British children. By
2 years, half of Pakistani children were EBV infected com-
pared to a quarter of White British children. The higher
incidence of CMV and EBV infection among Pakistani
children cannot be fully explained by differences in breast-
feeding, family size, childcare and socio-economic indica-
tors. VZV incidence from 12 to 24 months was lower
among the Pakistani than White British children. Risk fac-
tors for CMV and EBV infection differed by ethnic group.
Our VZV estimates are similar to those from previous UK
studies [18, 24]. In the Millennium Cohort Study, children
from other ethnic groups were less likely to have had
chickenpox by age 3 years than white children, based on
maternal report, similar to our findings [18]. There is good
evidence that VZV seroprevalence in the UK is lower among
pregnant women born in Asia than those born in the UK
[13, 25], due to later age at infection in many tropical coun-
tries compared to the UK. However, it is unclear why chil-
dren born to Asian women in the UK are infected later, as
VZV is predominantly transmitted between children rather
than from contact with the mother. It has been suggested
that infection with CMV affords some cross-protection
against VZV [18, 26] which could explain the later VZV in-
fection in Pakistani children in our study as they are infected
with CMV earlier than the White British children.
Our CMV incidence results were similar to a cross-
sectional study in the Netherlands [27]. CMV seropreva-
lence in 1- and 2-year-olds in a US study was lower than
our overall results, although there were small numbers of
children in each age group (<200) [11]. The only other UK
study on CMV prevalence in young children was based in a
London hospital 30 years ago and 20% of children were in-
fected by 12 months [16]. Results from Australia and
Sweden showed slightly higher seroprevalence at 2 years
[28, 29]. Our CMV results on breastfeeding, childcare and
socio-economic indicators are consistent with previous find-
ings and we report novel results on birth order (Table 5).
Ethnicity was a key risk factor in several studies with
consistent findings of higher CMV prevalence among
children in non-white ethnic groups compared to white/
European/Western groups [11, 27, 30]. This association
was specifically investigated in relation to other factors
in studies in New Zealand [31] and the Netherlands [32]
in children aged 3.5 and 6 years, respectively. Differences
by ethnic group could not be explained by differences in
parity, day care, breastfeeding, and socio-economic indi-
cators, similar to our findings.
The unexpected apparent protective effect of higher
birth order on early CMV infection among Pakistani chil-
dren is unlikely to be spurious for several reasons. First,
the birth order effect commonly associated with childhood
infections (i.e. children of higher birth order more likely
to be infected earlier) was observed for VZV in our study.
Second, estimates for the White British children are also
less than one although the confidence intervals cross one.
Third, Jansen et al. report a similar finding; multiparity
was inversely associated with CMV seropositivity by age
6 years (OR 0.76, 95% CI 0.65–0.90) [32]. The ‘birth order
effect’ is usually discussed in relation to the hygiene hy-
pothesis and refers to the lower risk of atopic disease
among children of higher birth order due to increased ex-
posure to childhood infections [15]. An alternative or con-
tributing explanation for this effect could be changes in
the maternal immune system with increasing parity so
that the effect is determined in the prenatal period [33].
Whether these changes could also affect the maternal im-
mune response to CMV infection and thereby the risk of
transmitting virus to her child (e.g. through breastmilk)
warrants further investigation. Perhaps CMV infection in
the first child acts like a vaccine to boost maternal im-
munity so she has lower viral load and takes longer to
infect subsequent children. Any such effect might be
manifest through acquiring immune responses to strains
of CMV different from the initial maternal infection, be-
cause prototype CMV vaccines can boost the immunity of
seropositive adults [8, 34, 35].
Table 5 Summary of main associations with age at infection
CMV EBV VZV
Associated with earlier infection White British • household sizec
• breastfeeding >6mb [16, 32, 42]
• formal childcare in 1st yrb [32]
• not owner-occupied householdb [11]
• informal childcare <1165 hrsc • birth orderb [18]
Pakistani • breastfeedingb
• mother born outside UK/Ireland c
• bedroom sharing in 1st yrb [21] • birth orderb
Associated with later infection White British - • mother/baby activities in 1st yra -
Pakistani • birth ordera
• travel outside Europe in 1st yr*b
- • maternal agea
anovel associations
bprevious studies with similar findings (refs)
cexpected association
*assuming this reflects higher socio-economic position
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Our EBV incidence estimates are comparable to re-
sults from previous UK studies [36–38]. Differences in
paediatric EBV prevalence by ethnic group have been re-
ported from two US studies [22, 39] and one in the
Netherlands [32]. Socio-economic position and family
size partly explained the ethnic differences observed in
the Generation R study [32] but the lower prevalence in
white children could not be explained by infection risk
factors in the Minnesota study [39].
The unexpected association between attendance at
mother/baby activities and later EBV infection among
White British children may have arisen due to uncon-
trolled confounding by socio-economic factors; further in-
vestigation did not provide convincing evidence of a real
effect as the association was only evident in a sub-group.
Ethnic differences in paediatric CMV and EBV inci-
dence have not been reported before in the UK but our
results are in line with findings in different populations.
As these cannot be fully explained by factors influencing
exposure to infection, genetic variation may play a role.
For example, the prevalence of the NKG2C deletion is
known to vary between populations and is important in
NK cell responses to CMV infection such that individ-
uals with the deletion are less able to control CMV vir-
aemia so CMV may be more easily transmitted [40].
Genetic susceptibility may also be important in infec-
tious mononucleosis following EBV infection [41].
A key strength of this study is having serology data at
two time points early in childhood. Previous studies have
been cross-sectional or with samples available for only one
time point. Our results demonstrate that most of the
CMV infections occurred in the first year and are generally
due to contact with the mother, whereas most EBV and
VZV infections are acquired in the second year through
contact with siblings and other children. Pinpointing age
at infection is important when examining associations with
subsequent development of atopic disease [42, 43] as there
is likely to be a critical window in immune development in
the first 2 years during which infection with CMV and/or
EBV may influence immune-related outcomes.
We collected detailed information on likely sources of
exposure to infection, with few missing values due to
interviewer-administered questionnaires with well-trained
interviewers. This study had the statistical power to inves-
tigate differences in acquisition of infection between two
large ethnic groups and the advantages of a prospective
birth cohort design with rich characterisation and homo-
geneity within ethnic groups. There were few differences
between the children in this analysis and the main BiB co-
hort and our results are generalisable to other multi-ethnic
urban UK populations. Our results may not be generalis-
able to less deprived populations within the UK where the
incidence of CMV and EBV infection by age 2 years is
likely to be lower than in Bradford.
A limitation of our study is that maternal CMV serosta-
tus was unavailable for most children. Adjustment for
mother’s country of birth and maternal age would have
partially accounted for maternal serostatus as South Asian
women born abroad have higher seroprevalence than
those born in the UK [13] and seroprevalence increases
with age. The pattern of higher incidence at 12 months in
Pakistani than White British children was still evident in
the sub-group of CMV seropositive women.
Misclassification of age at CMV and VZV infection due to
the occasional presence of maternal antibody at 12 months
is likely to have had a minimal effect; the adjusted incidence
figures rounded to the same percentage points.
Conclusions
This study provides current incidence data for three com-
mon herpesviruses in young children which are generalis-
able to urban UK populations. We have demonstrated
large differences in incidence between White British and
Pakistani children for the first time in the UK and have
identified key risk factors for infection in each group,
some novel, which suggest mechanisms of transmission to
be investigated further.
Our data will inform the optimum schedule of potential
CMV and EBV vaccination programmes. For CMV it has
been proposed that toddlers as well as adolescents are vac-
cinated to prevent transmission to pregnant women and re-
duce the risk of congenital CMV infection [9]. Our results
suggest that infants of Pakistani origin would need to be
vaccinated before age one and the impact of vaccinating
children with recent natural infection needs to be explored.
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